Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial.
暂无分享，去创建一个
D. Generali | M. Brizzi | A. Bottini | L. Dogliotti | M. Tampellini | A. Berruti | A. Bersiga | S. Bonardi | G. Allevi | B. Tondelli | S. Aguggini | F. Vana | P. Alquati | G. Bolsi